Skip to content

Study · Non-randomized trial · 2020

4 results

Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.

Terauchi Y, Yabe D, Kaneto H, Amano A, Baxter M, Watanabe D, Watada H, Inagaki N

Diabetes, obesity & metabolism1 Sept 2020Cited by 7 (Europe PMC)

PMID33404200 (opens in a new tab)DOI10.1111/dom.14139 (opens in a new tab)PepBankPUB-33404200
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In Japanese patients with diabetes, gastrointestinal disorders were more frequent with iGlarLixi than insulin glargine across age subgroups.

    In plain wordsGastrointestinal disorders were more frequent with iGlarLixi than insulin glargine across age subgroups.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGastrointestinal disorders across age subgroups
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Across age subgroups, incidences of gastrointestinal disorders with iGlarLixi were higher vs iGlar, but lower vs Lixi.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese people with type 2 diabetes in JP-O2, median time to HbA1c or fasting plasma glucose control was shorter with iGlarLixi than with insulin glargine.

    In plain wordsIn Japanese people with type 2 diabetes, median time to reach HbA1c or fasting glucose control was shorter with iGlarLixi than with insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTime to HbA1c or FPG control (JP-O2)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Median time to HbA1c or FPG control was shorter with iGlarLixi vs iGlar.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Japanese patients with diabetes, iGlarLixi reduced HbA1c more than insulin glargine across baseline subgroups.

    In plain wordsiGlarLixi reduced HbA1c more than insulin glargine across baseline subgroups in Japanese patients with diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction across subgroups
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HbA1c reductions were consistently greater with iGlarLixi vs iGlar or Lixi across all subgroups, and iGlarLixi was equally effective in all subgroups.
  4. 04HumanNon-randomized trialSafety outcome

    In Japanese patients with diabetes, documented symptomatic hypoglycaemia was generally comparable with iGlarLixi and insulin glargine.

    In plain wordsDocumented symptomatic hypoglycaemia was generally comparable with iGlarLixi and insulin glargine in Japanese patients with diabetes.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedDocumented symptomatic hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Incidences of documented symptomatic hypoglycaemia (plasma glucose ≤3.9 mmol/L) were higher with iGlarLixi vs Lixi and generally comparable with iGlar.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.